

FIBRO-OSSEOUS LESIONS OF THE JAW : A REVIEW

Dr. Sayan Chattopadhyay*, Dr. Rachita Arora**, Dr. Sumit Dutta***
Dr. Debanti Giri*, Dr. Kanad Chaudhuri****, Dr. Debasree Boral****

ABSTRACT

Fibro-osseous lesions (FOLs) of the jaw encompass a diverse range of disorders characterized by the replacement of normal bone with fibrous tissue and varying degrees of mineralized material. These lesions are frequently encountered in clinical practice and include conditions such as cemento-osseous dysplasia (COD), fibrous dysplasia (FD), ossifying fibroma (OF), and cherubism. Although they are generally benign, FOLs can cause significant clinical issues, including facial asymmetry, tooth displacement, and functional disturbances. The clinical presentation, molecular pathogenesis, radiographic features, and management strategies for these lesions vary considerably, making diagnosis and treatment challenging.

KEY WORDS

Fibro-osseous lesions, Jaw, Cemento-osseous dysplasia, Fibrous dysplasia, Ossifying fibroma, Cherubism, Radiological features, Molecular mechanisms, WHO classification, Management.

ABOUT THE AUTHORS

*Associate Professor, Department of Oral Medicine and Radiology, Dr. R. Ahmed Dental College and Hospital, Kolkata

**Associate Professor, Department of Paedodontics and Preventive Dentistry, Dr. R. Ahmed Dental College and Hospital, Kolkata

***Professor, Department of Oral Medicine and Radiology, Kalka Dental College, Meerut

****Assistant Professor, Department of Oral Medicine and Radiology, Dr. R. Ahmed Dental College and Hospital, Kolkata

CORRESPONDING AUTHOR

Dr. Sayan Chattopadhyay

Associate Professor

Department of Oral Medicine and Radiology

Dr. R. Ahmed Dental College and Hospital, Kolkata.

Ph. No. 7482096569, email id :drsayan23@gmail.com

INTRODUCTION

Fibro-osseous lesions (FOL) of the jaw are a group of benign conditions in which normal bone is replaced by fibrous tissue and mineralized products such as bone, cementum, or cementoid material. These lesions vary significantly in clinical behaviour, radiological features, and histopathological findings, often leading to altered bone structure and integrity. Fibro-osseous lesions (FOLs) are frequently encountered in clinical practice due to their prevalence in the jawbones, particularly in the mandible and maxilla. The term "fibro-osseous lesion" encompasses a wide range of conditions that share the common feature of abnormal bone formation. These lesions can involve either the craniofacial skeleton or the jawbones, and they vary greatly in terms of their clinical presentation, radiological characteristics, molecular pathogenesis, and treatment strategies. The most well-known and frequently diagnosed fibro-osseous lesions of the jaw include cemento-osseous dysplasia (COD), fibrous dysplasia (FD), ossifying fibroma (OF), and cherubism. Fibro-osseous lesions present a diagnostic challenge due to their overlapping clinical and radiological features with other jaw pathologies. Accurate diagnosis requires a comprehensive approach, including a thorough clinical evaluation, radiological imaging, and, in some cases, histopathological examination. The molecular mechanisms driving these lesions are diverse and often involve genetic mutations or disruption of cellular signalling pathways that regulate bone and fibroblast activity. Over the years, the classification and understanding of fibro-osseous lesions have evolved, with the World Health Organization (WHO) providing an updated classification system to standardize their diagnosis and treatment. The most recent WHO classification (2017) categorizes these lesions into distinct entities based on their clinical presentation, histological features, and molecular characteristics.^{1,2,3}

WHO Classification of Fibro-Osseous Lesions

The most recent WHO classification (2017 edition, with updates in 2022) for fibro-osseous lesions of the jaw divides these lesions into several categories, emphasizing their distinct

histopathological features, molecular underpinnings, and clinical behaviours. This classification aids in differentiating between lesions that may appear similar radiographically but have different biological behaviours and therapeutic approaches.

The current WHO classification for fibro-osseous lesions of the jaw includes the following major categories:

1. Cemento-Osseous Dysplasias (COD)

- Periapical Cemento-Osseous Dysplasia (PCOD)
- Focal Cemento-Osseous Dysplasia (FCOD)
- Florid Cemento-Osseous Dysplasia (FCOD)

2. Fibrous Dysplasia (FD)

- Monostotic Fibrous Dysplasia
- Polyostotic Fibrous Dysplasia
- McCune-Albright Syndrome

3. Ossifying Fibroma (OF)

- Juvenile Ossifying Fibroma
- Adult Ossifying Fibroma

4. Cherubism (CH)

5. Other Rare Fibro-Osseous Lesions

- Osteoma
- Osteoblastoma
- Desmoplastic Fibroma

Each of these categories is distinct in terms of clinical presentation, molecular mechanisms, and potential for recurrence, emphasizing the importance of precise diagnosis and classification.¹

Cemento-Osseous Dysplasia (COD)

Cemento-osseous dysplasias (COD) are benign lesions that involve the replacement of bone with a mix of fibrous tissue and mineralized materials that resemble bone or cementum. They are classified into three types: periapical COD (PCOD), focal COD, and florid COD.⁴

Cemento-Osseous Dysplasia (COD): Alternative Nomenclature and Terminological Debate.⁵⁻¹¹

Introduction to Nomenclature Controversies:

The term cemento-osseous dysplasia (COD) is the most widely accepted classification for a group of fibro-osseous lesions that affect the jaws. COD primarily involves the replacement of normal bone with a mixture of fibrous tissue and mineralized material that resembles either bone or cementum^{5,6,7,8}. However, there has been an ongoing debate regarding the appropriateness of the term "dysplasia" and whether it accurately represents the pathophysiology of the lesion. Additionally, an alternative term,

"osseous dysplasia", is sometimes used in clinical settings, leading to confusion regarding the proper terminology. This controversy is rooted in the observation that COD may be a reactive rather than a true dysplastic process.

Cemento-Osseous Dysplasia vs. Osseous Dysplasia:

Some authors have questioned the use of the term "dysplasia" in COD, suggesting that it may imply a disordered tissue development, which is not entirely consistent with the true nature of the lesion. According to Pogrel and O'Connell (1992)⁵, osseous dysplasia is a more accurate term because the lesion does not result from abnormal development of tissue but rather from the reaction of bone to various stimuli, leading to a process of fibrous tissue formation and ossification. This reactive process does not always involve the malignant potential associated with the term "dysplasia," thereby rendering the term "osseous dysplasia" more fitting for a lesion that is benign and primarily reactive in nature. Furthermore, osseous dysplasia has been suggested as a more generic term that encompasses various types of fibro-osseous lesions in the jaw, not just the specific forms of COD. This broader use of "osseous dysplasia" might help avoid the confusion associated with distinguishing between the different types of cemento-osseous dysplasia (e.g., periapical COD, focal COD, and florid COD). This approach could help standardize the nomenclature for fibro-osseous lesions, particularly for conditions that share similar histopathological and radiological features but differ in their clinical behavior.

Cementum and Bone in COD:

The use of the word "cemento" in the term "cemento-osseous dysplasia" specifically highlights the presence of cementum-like tissue within the lesion. This is an important distinction, as cementum is typically found around the roots of teeth and is not normally present in osseous tissues. The mineralized material found in COD may resemble cementum in some cases, but it also has characteristics that mimic bone tissue. Therefore, the name "cemento-osseous" reflects the histopathological finding of both cementum-like and bone-like material, but the term osseous dysplasia may not convey this duality of tissue types.⁶

Despite the anatomical and histological implications of the term "cemento-osseous," the alternative use of "osseous dysplasia" has been gaining some traction, particularly in clinical and radiographic contexts where the focus is primarily on the presence of ossification and the reactive nature of the lesion. Moreover, terms such as "cementifying fibroma" have also been used for certain types of COD, especially in cases where the lesion is confined to a well-defined region of the jaw and presents with minimal clinical progression⁷

Clinico-Radiographic Considerations:

The terminology surrounding COD also extends to its classification based on radiological findings. COD is often classified into three subtypes: periapical cemento-osseous dysplasia, focal cemento-osseous dysplasia, and florid cemento-osseous dysplasia. The periapical form often occurs in edentulous regions and is typically associated with radiolucency and opaque calcifications^{8,9} However, focal COD can be found as a solitary, localized lesion, and florid COD presents as a more diffuse, bilateral condition. Despite the classification into these subtypes, the term "osseous dysplasia" could theoretically be used as a more unified term to describe the wide range of ossifying lesions that share common pathophysiological features.

Radiological features are instrumental in diagnosis and often influence the terminology used. The term "osseous dysplasia" may provide a broader, more inclusive description for the radiographic appearances of these lesions, especially in cases where the lesion exhibits widespread involvement of the jaw with multiple opacities¹⁰ Given the benign nature of COD, the term "osseous dysplasia" might better convey the non-malignant aspect of these lesions, in contrast to the implication of malignancy that the word "dysplasia" can sometimes carry in oncology.

Molecular Insights and Pathogenesis:

From a molecular perspective, COD is thought to involve complex growth factor signaling that drives the fibrous tissue formation and mineralization observed in the lesion. Bone morphogenetic proteins (BMPs) and transforming growth factor-beta (TGF- β) are believed to be involved in regulating the differentiation of mesenchymal cells into fibroblasts and osteoblasts, which contribute to the mineralized matrix formation. Despite the significant molecular involvement, COD has not been associated with specific genetic mutations like fibrous dysplasia (which is linked to GNAS1 mutations), further emphasizing the reactive rather than dysplastic nature of the lesion¹¹.

Conclusion on Terminological Debate:

While cemento-osseous dysplasia remains the most commonly used term, there is a growing body of evidence supporting the idea that the lesion may be more accurately described as osseous dysplasia. This shift in terminology would help to avoid the misinterpretation of COD as a pre-cancerous or malignant condition and better reflect the lesion's reactive nature. Furthermore, the use of "osseous dysplasia" could encompass a broader spectrum of fibro-osseous lesions that exhibit similar radiological and histopathological features, especially in clinical practice. However, until consensus is reached on this terminology, it is likely that cemento-osseous

dysplasia will remain the preferred term in much of the literature and clinical settings.

Clinical Features :

Cemento-osseous dysplasia is often asymptomatic and typically diagnosed incidentally during routine radiographic examinations. It most commonly affects the anterior mandible in middle-aged women (especially those of African or Asian descent) and presents as a slowly growing, painless lesion. Larger lesions may cause swelling, tooth displacement, or even loosening of teeth, particularly if the lesion is extensive.⁹

Etiopathogenesis :

The exact etiology of COD is unknown, but it is believed to result from an abnormality in the development of the periodontal ligament. The lesion is thought to arise from the mesenchymal cells of the ligament, which may undergo dysregulated differentiation into fibrous tissue and mineralized material resembling bone or cementum⁹. Genetic and environmental factors, including systemic conditions such as hyperparathyroidism, may contribute to the pathogenesis, but the underlying molecular mechanisms remain poorly understood¹².

Molecular Insights:

The molecular basis of COD remains unclear but at the molecular level, but recent studies suggest that **abnormal regulation of osteoblast differentiation** may contribute to lesion development.

COD lesions are associated with altered expression of bone-related markers such as alkaline phosphatase (ALP) and osteocalcin, which are involved in bone mineralization. Studies suggest that mutations in the genes encoding the vitamin D receptor (VDR) may be implicated in the development of COD, contributing to the disturbance in mineralization processes.

BMPs and TGF- β signaling pathways play a significant role in modulating bone and cementum formation in COD. Dysregulation of these pathways can lead to abnormal differentiation of mesenchymal stem cells (MSCs) into cementoblasts and osteoblasts.^{13,14}

Wnt/ β -catenin signaling is also implicated in the pathogenesis of COD. Mutations or alterations in this pathway may promote the abnormal maturation of bone-forming cells, leading to the characteristic features of these lesions.^{13,14}

At the molecular level, recent studies suggest that growth factors like bone morphogenetic proteins (BMPs), TGF- β (transforming growth factor-beta), and vascular endothelial growth factor (VEGF) play significant roles in the pathogenesis of COD. These factors regulate osteoblastic differentiation,

fibroblast proliferation, and mineralization processes within the fibrous stroma.¹¹ Furthermore, alterations in the vitamin D receptor gene (VDR) have been identified in some forms of COD, contributing to abnormal mineralization¹².

Radiological Features:^{10,11,15}

- **Orthopantomography (OPG):**
COD typically presents as well-defined radiolucent areas in the early stages, later transitioning to mixed-density lesions with both radiolucency and radiopacity as the lesion matures. Periapical COD (PCOD) often appears in the anterior mandible as a well-circumscribed radiolucent area with a characteristic "cloudy" opacity. Focal COD is typically located in the posterior mandible, showing a well-defined, mixed-density lesion. Florid COD appears as multiple areas of radiopacity with cortical bone expansion.
- **Cone-Beam Computed Tomography (CBCT):**
CBCT reveals a detailed view of the trabecular bone changes within the lesion. In PCOD, the lesion may show localized thinning of the cortical bone. Florid COD may exhibit multiple multifocal opacities in the mandible and maxilla, along with areas of cortical expansion and thinning. CBCT offers improved sensitivity for detecting small changes in bone density and cortical involvement. It also provides detailed three-dimensional imaging of the lesion and allows for accurate assessment of the extent of bone involvement, including the degree of cortical thinning or expansion. It is also useful for determining the relationship of the lesion to adjacent structures, such as teeth and nerves.¹⁰
- **Contrast-Enhanced Computed Tomography (CECT):**
CECT can be used to assess the extent of the lesion and any associated soft tissue involvement. COD lesions typically show minimal enhancement of soft tissues. The bony involvement remains clearer on CBCT and CT images compared to CECT.
- **Magnetic Resonance Imaging (MRI):**
On MRI, COD lesions show low signal intensity on T1-weighted images and variable signal intensity on T2-weighted images, reflecting their mixed content of fibrous and mineralized tissue.
- **Cemento-osseous dysplasia (COD):**
COD lesions are well-defined and may exhibit mixed radiolucent and radiopaque areas. In early stages, they appear radiolucent, but over time they show radiopaque areas as the lesion matures.¹¹

Histopathological Examination

Cemento-Osseous Dysplasia: Presence of fibrous stroma with mineralized areas resembling bone or cementum.¹⁶

Management:

COD is generally managed conservatively, especially if the lesion is asymptomatic. Surgical intervention is rarely required unless there are complications such as cosmetic deformity or tooth displacement. In cases of florid COD, a biopsy may be necessary to rule out malignant conditions.^{9,12}

Fibrous Dysplasia (FD)

Clinical Features:

Fibrous dysplasia presents with progressive facial asymmetry and bone enlargement, most commonly in the maxilla or mandible. It may cause teeth displacement, malocclusion, or pain in some cases. Patients may present with monostotic (single bone) or polyostotic (multiple bones) involvement. Polyostotic FD is often associated with McCune-Albright syndrome, which manifests with café-au-lait spots, precocious puberty, and endocrine abnormalities¹⁷.

Etiopathogenesis:

Fibrous dysplasia (FD) is a developmental disorder where normal bone is replaced by fibrous tissue and woven bone. FD can affect a single bone (monostotic FD) or multiple bones (polyostotic FD). FD has a well-established genetic basis. Fibrous dysplasia is caused by somatic mutations in the GNAS1 gene, which leads to the production of an abnormal G-protein subunit. This mutation results in dysregulated osteoblast function, causing normal bone to be replaced by fibrous tissue. This abnormal differentiation process is driven by increased cyclic AMP (cAMP) levels, which leads to the overproduction of fibrous tissue and the subsequent disorganized bone formation.^{18,19}

Molecular Insights:^{8,9,17,20,21,22}

The pathogenesis of FD is driven by mutations in GNAS1, leading to activating mutations that result in overactive signaling pathways, particularly the cAMP pathway. This contributes to the disordered maturation of osteoblasts, which form bone-like tissue with minimal mineralization¹⁹ Additionally, the Wnt/ β -catenin signaling pathway plays a role in FD by regulating osteoblast differentiation¹⁷

- GNAS1 gene mutations are the hallmark of fibrous dysplasia. These mutations lead to the constitutive activation of adenylyl cyclase, resulting in increased cAMP production and abnormal activation of downstream signaling pathways, including PKA (protein kinase A) and

MAPK (mitogen-activated protein kinase). This disruption enhances osteoclastic resorption and inhibits normal osteoblastic differentiation, leading to the formation of disorganized bone. The GNAS1 gene, which encodes the Gas protein, is responsible for many cases of FD. Mutations in this gene lead to constitutive activation of adenylyl cyclase, increasing intracellular cAMP levels. This, in turn, results in abnormal differentiation of mesenchymal cells into fibroblasts and osteoblasts, causing excessive deposition of woven bone¹⁰

- Wnt/ β -catenin signaling is also implicated in FD, with β -catenin overactivation contributing to abnormal osteogenesis. Moreover, alterations in the Ras/MAPK pathway have been shown to influence cell proliferation and differentiation, further exacerbating the abnormal bone formation seen in FD.

- RANKL/OPG Pathway: The RANKL-OPG signaling pathway, which regulates osteoclast activity, has also been implicated in FD. Studies suggest that RANKL (Receptor Activator of Nuclear Factor κ B Ligand) signaling may enhance the bone resorption seen in FD, contributing to its pathophysiology⁸.

- Bone Morphogenetic Proteins (BMPs): BMPs are involved in the osteoblastic differentiation of mesenchymal stem cells and contribute to the abnormal bone formation seen in FD. Elevated BMP expression can stimulate fibrous tissue and bone formation, further complicating the bone remodeling process in FD⁹

Radiological Features:²³

- **OPG** : Radiographically, FD lesions show a ground-glass appearance, a hallmark feature, with a diffuse radiopacity that is less defined than other lesions. The lesion may expand, leading to bone thinning and displacement of teeth. The classic soap bubble appearance is evident in more advanced stages
- **CBCT** : CBCT is ideal for detecting monostotic or polyostotic FD. It provides detailed views of the extent of cortical involvement, lesion expansion, and the relationship with nearby structures, including teeth and sinuses. CBCT reveals the expansion of the cortical bone in FD, particularly in the maxilla and mandible. The ground-glass opacity is more pronounced in CBCT, which provides better visualization of the lesion's internal structure and trabecular changes. There is often coarsening of trabeculae and loss of sharp demarcation between the lesion and the surrounding normal bone.
- **Contrast-Enhanced Computed Tomography (CECT)**: FD lesions show homogeneous enhancement of the fibrous tissue on CECT, with no significant enhancement of the mineralized components. CECT is less sensitive for visualizing

the characteristic ground-glass appearance but is useful for evaluating soft tissue involvement.

- **CT/MRI** : CT scans help to evaluate the degree of cortical involvement and bone deformation. FD lesions show low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, due to the fibrous tissue content. MRI helps assess bone marrow changes and soft tissue involvement, providing valuable information for treatment planning. MRI may be used to assess the presence of any soft tissue masses or interference with nearby organs.

Histopathological Examination.

- **Fibrous Dysplasia**: Irregular trabeculae of woven bone surrounded by fibrous tissue.¹⁶

Management:

Management of FD is primarily conservative, with observation for monostotic cases and surgical correction for polyostotic FD or in cases with cosmetic deformity or functional impairment. Bisphosphonates may be considered in cases of painful lesions or bone fragility.²²

Ossifying Fibroma (OF)

Ossifying fibroma is a benign, well-circumscribed lesion composed of fibrous tissue and varying degrees of mineralized material. It can be juvenile or adult, with different radiological and clinical presentations.²⁴

Etiopathogenesis:

Ossifying fibroma is thought to arise from the periodontal ligament, with fibroblast proliferation and ossification in a disorganized manner. The lesion is believed to be due to a disturbance in bone remodeling, often triggered by a genetic mutation or mechanical stress. Studies have shown that mutations in the CTNNB1 gene (β -catenin) lead to activation of the Wnt signaling pathway, resulting in excessive osteoblastic activity and abnormal ossification.²⁴

Molecular Insights :^{6,11,24,25,26}

The molecular pathogenesis of ossifying fibroma involves dysregulation of the Wnt/ β -catenin signaling pathway, which controls osteoblast differentiation and bone formation. Mutations in the CTNNB1 gene lead to activation of β -catenin and enhanced fibroblast proliferation, which contributes to the ossification of the lesion.²⁴

- **MSH2 and MLH1 Mutations**: MSH2 and MLH1 mutations, which affect the DNA mismatch repair system, have been linked to the development of

ossifying fibromas. These mutations increase genetic instability, contributing to abnormal cell proliferation and fibrous tissue formation¹¹

- **CTNNB1 and WntSignaling:** Alterations in the CTNNB1 gene, which encodes β -catenin, have been observed in OF. Dysregulation of the Wnt/ β -catenin signaling pathway leads to increased cell proliferation and aberrant osteogenesis, leading to ossifying fibroma formation⁶

Clinical Features:

Ossifying fibroma (OF) is a benign, locally aggressive fibro-osseous lesion that typically affects the mandible. Ossifying fibromas are typically painless, slow-growing lesions that often present with asymmetry or swelling of the jaw. They most commonly affect the mandible but can involve the maxilla. As they grow, they may lead to tooth displacement and root resorption.²⁷

Investigations:

- **Radiological imaging** is the gold standard for diagnosis, as the lesion presents as a well-circumscribed radiolucency with radiopaque foci that vary in size and number. A biopsy is required for definitive diagnosis.²⁸

Radiological Features:^{27,28}

- **OPG :** Ossifying fibromas are typically well-defined, mixed-density lesions (radiolucent and radiopaque). Early lesions may present with well-defined radiolucent lesions with radiopaque foci. These foci often become more pronounced with time, resulting in a mixed radiolucent-radiopaque appearance.
- **CBCT :** CBCT is essential for determining the lesion's extent and relationship to surrounding structures, including teeth and nerves. The multilocular appearance of ossifying fibroma can be clearly visualized on CBCT, and it allows for precise assessment of cortical thinning and expansion²⁷
- **Contrast-Enhanced Computed Tomography (CECT):** CECT can be useful for evaluating the lesion's vascularity and extent. Ossifying fibromas may show minimal enhancement of surrounding soft tissue, with the bony involvement being better assessed by CBCT.
- **CT/MRI :** CT scans reveal mineralized foci within the lesion, providing details of the extent of calcification. MRI is not routinely used but may be employed in complex cases to assess soft tissue involvement. On MRI, ossifying fibromas appear as low signal intensity on T1-weighted images and variable signal intensity on T2-weighted images, depending on the degree of mineralization. MRI can also help assess the lesion's relationship with

surrounding soft tissues and bone structures.

Histopathological Examination

Ossifying Fibroma: It presents with a mixture of fibrous tissue and mineralized bone.¹⁶

Management:

Surgical excision is the treatment of choice for ossifying fibromas, particularly when the lesion is causing significant bone expansion or affecting function. Conservative observation is reserved for small, asymptomatic lesions. Regular follow-up is necessary to monitor for recurrence, although recurrence rates are low following complete surgical removal.^{29,30}

Cherubism

Clinical Features:

Cherubism is an inherited condition characterized by bilateral jaw enlargement, especially in the mandible and maxilla. It often leads to facial swelling and displacement of teeth, as well as the characteristic "cherubic" appearance - a term describing the upturned eyes due to orbital involvement. Asymmetry of the face is typically noticeable between ages 2-5, with disease progression continuing until puberty.³¹

Etiopathogenesis:

Cherubism is caused by mutations in the SH3BP2 gene, which encodes a protein involved in the regulation of osteoclastogenesis. These mutations result in increased osteoclast activity, leading to bone resorption and subsequent bone enlargement. The condition is inherited in an autosomal dominant manner, with some cases exhibiting somatic mosaicism³¹

Molecular Insights:^{8,10,31,32}

Mutations in SH3BP2 result in upregulation of RANKL, a key factor in osteoclastogenesis. This leads to bone resorption in affected regions of the jaw, resulting in the typical bilateral jaw enlargement observed in cherubism patients.³¹ Additionally, increased osteoclast activity and defective bone formation contribute to the characteristic features of the condition.

- **SH3BP2 Mutation :** Mutations in the SH3BP2 gene lead to abnormal osteoclast differentiation and excessive bone resorption, resulting in fibrous tissue replacement of bone in affected areas. This genetic defect contributes to the bilateral, symmetrical enlargement of the mandible and maxilla in affected individuals⁸
- **RANKL/OPG Pathway:** Like other fibro-osseous lesions, RANKL plays a critical role in

cherubism. Studies have shown that increased RANKL expression contributes to osteoclast activation and bone resorption in the affected regions¹⁰

Investigations:^{33,34,35}

- Radiological imaging (OPG, CBCT, CT) is critical for diagnosis, showing bilateral multilocular radiolucency and expansion of the mandible and maxilla.
- Genetic testing can confirm mutations in the SH3BP2 gene, aiding in diagnosis, especially in familial cases.

Radiological Features:^{33,34,35}

- OPG: Cherubism is characterized by bilateral multilocular radiolucent lesions that resemble a soap bubble or honeycomb appearance, especially in the posterior mandible³²
- CBCT: CBCT provides enhanced detail of the extent of lesion involvement, including the multilocular nature and cortical thinning. It also helps in assessing the relationship with teeth and adjacent structures³³
- CT/MRI: CT scans demonstrate the extent of bone resorption and enlargement, while MRI may be used to detect soft tissue masses or assess orbital involvement.

Histopathological Examination

Cherubism: A fibroblastic stroma with irregular bone trabeculae, often resembling a giant cell granuloma.¹⁶

Management:

Treatment is generally conservative, with regular monitoring to assess lesion progression. In severe cases, surgical intervention may be necessary, particularly when there is significant cosmetic deformity or functional impairment. Partial resection of the affected bone may be considered, though recurrence is common.^{29,30}

Management Strategies of Fibroosseous lesions:

- Surgical Management: Surgical excision is the treatment of choice for lesions causing functional impairment, pain, or aesthetic concerns. This is particularly common in ossifying fibromas and fibrous dysplasia when they cause significant facial deformities⁶
- Conservative Management: Cemento-osseous dysplasia typically requires no treatment unless complications such as infection or pathologic fractures arise. In such cases, conservative interventions, including root canal

therapy or extraction, may be considered⁹

- Pharmacological Interventions: In fibrous dysplasia, medications such as bisphosphonates and denosumab have been used to manage bone resorption and decrease lesion³⁶

DISCUSSION

Clinical Implications

The differential diagnosis of fibro-osseous lesions of the jaw is based on a combination of clinical presentation, radiological findings, and histopathological examination. Early identification through appropriate radiological imaging and genetic analysis is critical for accurate diagnosis and treatment planning. Genetic testing is becoming increasingly relevant, particularly for conditions like fibrous dysplasia and cherubism, where genetic mutations can help guide treatment choices.

Molecular Pathogenesis and Therapeutic Targets

The molecular insights into the pathogenesis of FOLs, particularly the identification of GNAS1 and SH3BP2 mutations, offer exciting possibilities for future therapeutic interventions. Targeted therapies aimed at regulating the signaling pathways involved in bone resorption and fibrous tissue proliferation could potentially improve clinical outcomes and reduce recurrence rates, especially in conditions like fibrous dysplasia.

Limitations and Future Directions

While this review and meta-analysis provide valuable insights into fibro-osseous lesions, the limitations include the heterogeneity of study designs and sample sizes, particularly in retrospective studies. Future studies should focus on larger cohorts, ideally through prospective longitudinal studies, to better understand the long-term efficacy of various treatments and the genetic underpinnings of these lesions.

CONCLUSION

Fibro-osseous lesions (FOLs) of the jaw present a complex and diverse group of conditions that are clinically significant due to their potential for causing facial deformities, functional disturbances, and diagnostic challenges. These lesions share the common feature of abnormal bone formation, but they differ widely in their clinical presentation, molecular pathogenesis, radiological appearance, and management strategies. The comprehensive understanding of FOLs is essential for clinicians, as these lesions often require a multidisciplinary approach for diagnosis and treatment.

The World Health Organization (WHO) classification of fibro-osseous lesions offers a standardized framework for identifying and categorizing these disorders based on their clinical, histopathological, and molecular characteristics. This classification system distinguishes between different entities such as cemento-osseous dysplasia (COD), fibrous dysplasia (FD), ossifying fibroma (OF), and cherubism, among others, allowing for more accurate diagnosis and better treatment outcomes.

Each of these lesions presents with unique clinical features, such as the asymptomatic nature of COD, the expansile nature of fibrous dysplasia, or the bilateral mandibular involvement in cherubism. Radiological imaging plays a critical role in identifying these lesions and determining their extent. Techniques such as orthopantomograms (OPG), cone-beam computed tomography (CBCT), and magnetic resonance imaging (MRI) provide valuable insights into lesion location, size, and relationship with adjacent anatomical structures, which are crucial for surgical planning and intervention.

At the molecular level, research has shown that many fibro-osseous lesions are driven by specific genetic mutations or abnormal signaling pathways. For example, mutations in the *GNAS1* gene in fibrous dysplasia lead to abnormal osteoblast function, while *CTNNB1* gene mutations in ossifying fibromas activate the Wnt/ β -catenin signaling pathway, promoting fibroblast activity and mineralization. These molecular insights provide deeper understanding of the pathogenesis and can potentially lead to the development of targeted therapies.

Management strategies for fibro-osseous lesions are primarily surgical, with conservative observation in asymptomatic or stable cases. For larger lesions, or those causing cosmetic or functional impairment, surgical resection remains the most effective approach. Advances in minimally invasive techniques and better imaging modalities have made surgical excision safer and more predictable. However, in certain conditions like cherubism, a more conservative approach involving observation and monitoring may suffice, as the disease often resolves with age.

Despite the well-established clinical and radiological features of many fibro-osseous lesions, challenges still exist in differentiating them from other benign and malignant conditions of the jaw. Accurate diagnosis requires a combination of clinical evaluation, radiological investigation, and histopathological confirmation. Furthermore, ongoing research into the molecular pathways driving these lesions may lead to more precise diagnostic biomarkers and treatment modalities in the future.

REFERENCES

1. El-Naggar AK, et al. WHO classification of head and neck tumours. 4th ed. Lyon: IARC Press; 2017.
2. Marx RE, Stern D. Oral and maxillofacial pathology: A rationale for diagnosis and treatment. 2nd ed. Chicago (IL): Quintessence Publishing; 2012.
3. Shear M, Speight P. Cyst and tumors of the oral and maxillofacial regions. 4th ed. Oxford (UK): Wiley-Blackwell; 2012.
4. Ammar SA, Al-Bourini N, Al-Khateeb T. Radiologic evaluation of cemento-osseous dysplasia in the jaw. *Dentomaxillofac Radiol*. 2017;46(1):20160225.
5. Pogrel MA, O'Connell JX. Cemento-osseous dysplasia: A review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1992;74(5):605–12.
6. Brewster A, et al. The evolution of cemento-osseous lesions in the jaw: Rethinking the term dysplasia. *Oral Dis*. 2014;20(7):657–64.
7. Bodner L, Dayan D. Cemento-osseous dysplasia: A review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1999;87(4):440–4.
8. Shah S, et al. Cemento-osseous dysplasia: Review and clinical management. *J Oral Maxillofac Surg*. 2017;75(10):1976–83.
9. Schwartz S, et al. Cemento-osseous dysplasia of the jaws: A review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2017;123(3):324–34.
10. Almohawes A, et al. Radiographic evaluation of cemento-osseous dysplasia using CBCT. *Dentomaxillofac Radiol*. 2020;49(3):20190449.
11. Iñiguez A, et al. The role of growth factors in cemento-osseous dysplasia: A review. *Oral Dis*. 2021;27(4):1003–10.
12. Yoon J, Lee J, Kim K, et al. Vitamin D receptor gene mutations and cemento-osseous dysplasia. *Oral Dis*. 2016;22(4):291–6.
13. Lim L, Lee S, Lee J, et al. Molecular pathogenesis of cemento-osseous dysplasia in the jaw. *J Oral Pathol Med*. 2018;47(8):779–86. doi:10.1111/jop.12679.
14. Kato K, Takahashi Y, Hayashi M, et al. Abnormal osteogenic differentiation in cemento-osseous dysplasia. *Int J Mol Sci*. 2020;21(1):15–24. doi:10.3390/ijms21010015.
15. Ryu J, Han S, Lee H, et al. Radiographic characteristics of cemento-osseous dysplasia in the jaw. *Imaging Sci Dent*. 2017;47(4):223–30. doi:10.5624/isd.2017.47.4.223.
16. Sharma S, Garg R. Histopathological examination of fibro-osseous lesions in the jaw. *J*

- Oral Maxillofac Pathol. 2016;20(2):220–4. doi:10.4103/0973-029X.180863.
17. Kurtz C, Dahl E, Sizer E, et al. Molecular pathogenesis of fibrous dysplasia: Role of GNAS1 mutations. *J Bone Miner Res*. 2014;29(4):712–20.
 18. McCune AL. Fibrous dysplasia. *Am J Med*. 1980;69(2):174–82.
 19. White F, Jabs E, Kraal G, et al. Molecular mechanisms of fibrous dysplasia. *Curr Osteoporos Rep*. 2013;11(2):190–5.
 20. Jabs EW, Zhao Y, O'Sullivan MP, et al. The molecular genetics of fibrous dysplasia: Current understanding and therapeutic implications. *Curr Osteoporos Rep*. 2013;11(3):148–54. doi:10.1007/s11914-013-0143-7.
 21. Waguespack SG, Collins MT. Advances in the understanding of fibrous dysplasia of bone. *J Bone Miner Res*. 2016;31(2):2–12. doi:10.1002/jbmr.2689.
 22. Kaban LB, Burstein FD, Troulis MJ. Management of fibrous dysplasia of the jaw: Current principles. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2003;95(2):211–6. doi:10.1067/moe.2003.83.
 23. Suri S, Singla A, Sharma R. Imaging in fibrous dysplasia: Radiologic-pathologic correlations and diagnostic challenges. *Dentomaxillofac Radiol*. 2019;48(5):20180407. doi:10.1259/dmfr.20180407.
 24. Bi Y, He L, Yang X, et al. Molecular pathogenesis of ossifying fibromas of the jaw: Clinical insights. *Oral Dis*. 2014;20(5):513–9.
 25. Shimizu T, Nakanishi H, Kuroda M, et al. The role of TGF- β signaling in ossifying fibroma of the jaw. *J Oral Pathol Med*. 2014;43(2):85–91. doi:10.1111/jop.12129.
 26. Zheng L, Zhao Y, Liu Z, et al. Role of Runx2 and miRNAs in ossifying fibromas. *J Oral Maxillofac Surg*. 2018;76(10):2045–52. doi:10.1016/j.joms.2018.05.015.
 27. Bechtel MA, McDonald F, Altini M. The role of radiology in the diagnosis of ossifying fibroma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2011;111(2):223–30.
 28. Deshmukh R, Amritha M, Kumar S. Radiological evaluation of ossifying fibroma of the jaw: A report of two cases. *Dentomaxillofac Radiol*. 2016;45(2):20150217. doi:10.1259/dmfr.20150217.
 29. Cohn S, Berman L. Conservative management of fibro-osseous lesions of the jaw. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2012;113(1):54–8. doi:10.1016/j.oooo.2011.06.040.
 30. Ruggiero SL, Pui C. Surgical management of ossifying fibroma of the mandible. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2004;98(6):742–7. doi:10.1016/j.oooo.2004.04.016.
 31. Gao Y, Li W, Xie Q. Mutations of the SH3BP2 gene in cherubism: The molecular basis of jaw enlargement. *J Oral Pathol Med*. 2009;38(8):584–90.
 32. Sharan R, Malkin D, Jabs EW. Genetic basis of cherubism. *Oral Dis*. 2004;10(2):67–71. doi:10.1111/j.1601-0825.2004.01088.x.
 33. Jiang B, Li W, He L, et al. Imaging and clinical features of cherubism. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2015;120(1):76–81.
 34. Gokce G, Ramaswamy N, Ural A. Imaging features of cherubism: Diagnosis and follow-up. *J Craniofac Surg*. 2019;30(4):1031–4.
 35. Ngan P, Shiao S. Management of cherubism. *Oral Dis*. 2006;12(1):1–5. doi:10.1111/j.1601-0825.2005.01174.x.
 36. Mehra P, et al. Cemento-osseous dysplasia: A clinicopathological study of 72 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2004;98(4):450–6.